A Chinese-made coronavirus vaccine has an efficacy rate just over 50%—far lower than the 78% anticipated, according to a Brazilian clinical trial conducted by São Paulo’s Butantan Institute.  

WHO investigators from 9 countries have arrived in Wuhan to look into the origins of the pandemic, following delays that triggered a rare rebuke from the agency.  

The issue is far from settled among economists and politicians, as NPR repor

One Friday last month, I posted a map on Twitter. It drew immediate global attention, was seen by 8 million people, and has provoked strong responses and anger—and hopefully some soul-searching among those in governments and pharmaceutical companies.

“The virus took Grandma Delores first, silencing an 86-year-old voice that rang with Lakota songs and stories.”  

The data show that communities of color have been hit the hardest in the pandemic—yet many still do not see systemic racism as a barrier to good health.  

Among the many challenges facing President-elect Joe Biden upon his inauguration on January 20, the most urgent is the US COVID-19 response. How will things change? What will be his strategies and priorities?

Infectious new coronavirus variants spell bad news for already-strained hospitals, the WHO said yesterday,

Amid supply shortages and persistent vaccine nationalism, it could be years before COVID-19 vaccines reach billions of people in low- and middle-income countries, the

Reports that some low-priority staff at some elite medical institutions are getting coronavirus vaccines ahead of their turn are stirring an ethical outcry,